EICHOR
● Completed
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Condition: Relapsed/Refractory Multiple Myeloma (RRMM) · Metastatic Colorectal Cancer (mCRC) · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Sponsor: Karyopharm Therapeutics Inc
About this study
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (46)
| David Geffen School of Medicine at UCLA | Los Angeles, California, United States | — |
| Oncology Institute of Hope and Innovation | Pasadena, California, United States | — |
| Rocky Mountain Regional VA Medical Center | Aurora, Colorado, United States | — |
| Sarah Cannon Cancer Center - (Colorado Blood Cancer Institute) | Denver, Colorado, United States | — |
| (USO) Rocky Mountain Cancer Centers | Littleton, Colorado, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids, Michigan, United States | — |
| Sarah Cannon Cancer Center (HCA Midwest KC) | Kansas City, Missouri, United States | — |
| Callahan Cancer Center | North Platte, Nebraska, United States | — |
| John Theurer Cancer Center at Hackensack UMC | Hackensack, New Jersey, United States | — |
| University of New Mexico | Albuquerque, New Mexico, United States | — |
| Weill Cornell Medical College | New York, New York, United States | — |
+ 34 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02649790